PRESS RELEASES
Subscribe to our latest press releases
Aperio Increases Momentum in Response to Global Interest in Digital Pathology
Digital Pathology Leader Doubles Size of Product Development and Sales Teams, Expands Globally
Vista, CA – October 31, 2011 -
Aperio, the global leader in
providing digital pathology solutions that improve patient care, is
realizing a pronounced increase in demand for its digital pathology
solutions as a result of offering an increased breadth of products
designed to help pathologists be more effective, including:
- Clinical workflow software for applications that include internal, external and intra-operative consultations, archival and retrieval, quantification of breast tissue biomarkers, tumor board preparation, and patient communication and education.
- The ScanScope® AT slide scanning instrument, configurable from 40 to 400 slides, which provides customer with the lowest cost per slide, highest throughput and smallest footprint.
- The ScanScope® FL slide scanning instrument with industry-leading reproducibility for the quantification of multiple fluorescent biomarkers.
- Access to Definiens™ Tissue Studio from Aperio’s integrated image management and analysis environment.
“Our clinical workflow solution is the direct results of staying close to our customers” said
Jared N. Schwartz, Chief Medical Officer of Aperio.
“We are pleased by the strong customer response to this new offering, which is a
reflection of our focus on creating solutions designed to increase the
productivity and efficiency of pathologists and to enable them to deliver more
precision and personalized care to patients.”
Building on a global installed base of over 850 systems in more than 30 countries—more than all of its competitors, combined—Aperio has increased its investment in key areas to respond to this growing demand, including (i) doubling the size of its instrument and software development teams, (ii) tripling the size of its product management team, (iii) doubling the size of its healthcare sales team, and (iv) opening an office in China. In 2011 Aperio has added over 50 new staff to its team of over 220 employees. Significant contracts signed with leading customers include:
- Allina Health System, Minneapolis, MN
- Brigham & Women’s Hospital, Boston, MA
- Inova Fairfax Hospital, Washington, DC
- Mayo Clinic, Jacksonville, FL
- Pocono Medical Center, East Stroudsburg, PA
- University of Michigan Health System, Ann Arbor, MI
- Labmedicin Skåne, Lund, Sweden
- Bergen University Hospital, Bergen, Norway
- Gavle Hospital, Gavle, Sweden
- University of Western Ontario – Victoria Research Labs, London, ON
- Thomas Jefferson University – Kimmel Cancer Center, Philadelphia, PA
- NeoGenomics Laboratories, Fort Myers, FL
- Washington DC VA Medical Center, Washington, DC
- Medtronic, Santa Rosa, CA
- EMD Millipore, Temecula, CA
- MPI Research, Mattawan, MI
- Imclone, New York, NY
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- Merrimack Pharmaceuticals, Cambridge, MA
- Metamark Genetics, Cambridge, MA
“At Aperio we understand the key elements of digital pathology—pathology, workflow and information technology—better than anyone else,” said
Dirk G. Soenksen, CEO of Aperio. “Our industry-leading installed base gives us the unique ability to provide customers with an informed view of best practices in digital pathology, and to provide them with proven, scalable and cost-effective digital pathology solutions.”
About Aperio
Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists’ skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® slide sharing service for pathology, and image analysis tools and services. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information please visit www.aperio.com.
Contacts:
Tasha Hicks
Director, Marketing
Aperio
760.539.1118
tasha@aperio.com